Company profile: Bio-Techne
1.1 - Company Overview
Company description
- Provider of tools for life science research, therapeutic manufacturing, and clinical diagnostics, including automated protein analysis (Simple Western), automated ELISA (Ella), bead-based multiplex assays (Luminex), non-viral gene transfer (TcBuster), recombinant antibodies, and custom bioactive compound libraries (Tocriscreen PRO) for research, drug discovery, and cell engineering.
Products and services
- Luminex Assays: Bead-based immunoassays enabling multiplexing of up to 50 analytes in a single sample for research and clinical diagnostics
- Ella Automated ELISA: Benchtop platform that automates ELISA assays, delivering fast and reproducible multiplexing results with minimal manual intervention
- Simple Western: Capillary-based automated western system for protein separation and immunodetection, offering gel-free and blot-free analysis of proteins
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bio-Techne
Tentarix
HQ: United States
Website
- Description: Provider of protein therapeutics and discovery platforms leveraging synthetic biology, including the Tentacles platform for multifunctional, conditionally active antibody-based biologics that activate immune cells and modulate disease while minimizing safety concerns; CellSurf to understand cell surface proteomes; HuTARG mammalian display to discover fully human binders; and FunctionSeq high-throughput screening of multifunctional biologics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tentarix company profile →
ONI
HQ: United Kingdom
Website
- Description: Provider of super-resolution microscopy solutions, making this advanced technology accessible to new generations of researchers. Offers the Nanoimager, the world's first benchtop-sized super-resolution microscope, delivering a step change in usability and precision, together with next-generation consumable products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ONI company profile →
Stilla Technologies
HQ: France
Website
- Description: Provider of digital PCR solutions to accelerate next-generation genetic testing, including the Nio System, an all-in-one 7-color, continuous-loading instrument for high-throughput analysis; the naica System, a multiplex dPCR platform with up to six fluorescent channels; ready-to-use digital PCR kits and assays; chips and reagents; and analysis software for image analysis and data export.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stilla Technologies company profile →
Elegen
HQ: United States
Website
- Description: Provider of cell-free DNA synthesis solutions, including ENFINIA DNA producing long, complex linear DNA up to 7kb with 99.999% per-base accuracy, shipped in 6 to 8 business days; high-complexity DNA synthesis for challenging sequences like long repeats and GC-rich regions, with delivery as fast as 10 business days; and an Early Access Program for pre-commercial products, including sequences longer than 15,000 base pairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elegen company profile →
Mimetas
HQ: The Netherlands
Website
- Description: Provider of predictive Organ-on-a-Chip cell culture tissue and disease models via its OrganoPlates featuring organotypic screening models, improving predictability over in vitro and animal models to enable better, more reliable, and tailored medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mimetas company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bio-Techne
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bio-Techne
2.2 - Growth funds investing in similar companies to Bio-Techne
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bio-Techne
4.2 - Public trading comparable groups for Bio-Techne
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →